Contact
Please use this form to send email to PR contact of this press release:
Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
TO:
Please use this form to send email to PR contact of this press release:
Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)
TO: